arrow
T

Takashi Matsuki

kitasato university
H指数:20
被引数:1,865

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hematological Markers Predict Immune-Related Adverse Events in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Pembrolizumab

血液学标志物可预测接受帕博利珠单抗治疗的复发或转移性头颈部鳞状细胞癌患者的免疫相关不良事件

2025-09-010
PRE
The impact of HER2-Low expression in salivary duct carcinoma: Clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapy

HER2-Low表达在涎腺导管癌中的影响:临床病理特征、生存结局及其与雄激素受体靶向治疗的关联

2025-06-010
PRE
PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab

PD-L1表达作为使用pembrolizumab治疗的复发或转移性唾液腺癌患者的预测生物标志物

2024-08-270
OAAI
Prognostic value and clinicopathological roles of the tumor immune microenvironment in salivary duct carcinoma

肿瘤免疫微环境在涎腺导管癌中的预后价值及临床病理作用

2023-07-194
PRE
Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma

HER2-targeted或雄激素剥夺疗法在涎腺导管癌中的生存益处

2022-09-0619
OAAI
The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy

EZH2和H3K27me3表达作为涎腺导管癌患者临床预后预测指标的作用: 一项大型系列研究,重点是雄激素阻断和HER2-Targeted联合治疗的相关性

2022-02-0315
OAAI
Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma

纳武利尤单抗治疗复发和转移性涎腺癌的疗效和安全性的多中心回顾性研究

2020-10-1231
OAAI